Shanghai Junshi Biosciences (HKG:1877, SHA:688180) agreed to license JS005 to Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) for the greater China region, according to a Wednesday filing with the Hong Kong bourse.
The company will receive an upfront payment of 215 million yuan, plus a further 1.13 billion yuan in milestone-related payments.
Junshi Biosciences will also receive royalty payments once the drug is commercialized in the greater China region.
JS005, also known as roconkibart, is a treatment for autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis.